KALA BIO, Inc. (FRA:27F0)

Market Cap	12.60M -61.7%
Revenue (ttm)	n/a
Net Income	-30.55M
EPS	-4.96
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	1,591
Open	0.4310
Previous Close	0.4564
Day's Range	0.4310 - 0.4310
52-Week Range	0.4310 - 16.9900
Beta	n/a
RSI	35.55
Earnings Date	Mar 27, 2026

About KALA BIO

KALA BIO, Inc. a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare and severe eye diseases. The company’s lead product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; and limbal stem cell deficiency and other rare corneal diseases. Its preclinical development product consists of KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, In...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2009
• Employees: 38
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 27F0

Financial Performance

Financial numbers in USD